Drug intelligence / Profile preview

PVX-001

Development stage: Preclinical
Lead developer: PopVax
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PVX-001 is an mRNA-based vaccine candidate being developed by PopVax for the prevention of COVID-19. Designed as a broadly-protective vaccine, it aims to provide immunity against multiple variants of the SARS-CoV-2 virus. The program is currently in the IND-enabling stage, with a Phase I clinical trial anticipated to begin in Australia in mid-2026. The vaccine leverages PopVax's proprietary mRNA platform to induce robust immune responses.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on PVX-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVX-001.

Explore the full profile